Since autophagy mediated by ATG7 is often disrupted in metabolic dysfunction, we wanted to study hepatic ATG7 mRNA and ATG7 protein expression in patients classified according to the presence of comorbidities associated with NAFLD (dyslipidemia, T2DM, hypertension, and metabolic syndrome) other than obesity. This evidence concerns the gene ATG7 and metabolic syndrome.